Synthesis and Platelet Aggregation Inhibiting Activity of Acid Side-chain Modified Hydantoin Prostaglandin Analogues

1993 ◽  
Vol 326 (2) ◽  
pp. 85-95 ◽  
Author(s):  
Paul Barraclough ◽  
A. Gordon Caldwell ◽  
Robert C. Glen ◽  
C. John Harris ◽  
Ray Stepney ◽  
...  
Author(s):  
Paul Barraclough ◽  
A. Gordon Caldwell ◽  
C. John Harris ◽  
William P. Jackson ◽  
Brendan J. R. Whittle

ChemInform ◽  
1990 ◽  
Vol 21 (4) ◽  
Author(s):  
P. BARRACLOUGH ◽  
A. G. CALDWELL ◽  
C. J. HARRIS ◽  
W. P. JACKSON ◽  
B. J. R. WHITTLE

1984 ◽  
Vol 15 (8) ◽  
Author(s):  
G. L. BUNDY ◽  
D. R. MORTON ◽  
D. C. PETERSON ◽  
E. E. NISHIZAWA ◽  
W. L. MILLER

1979 ◽  
Author(s):  
K. U. Weithmann ◽  
W. Bartmann ◽  
G. Beck ◽  
U. Lerch ◽  
E. Konz ◽  
...  

PGI2-analogs in which the n-pentyl moiety in position 15 was replaced by several residues, were subjected to structure-activity studies. Some of the modified PGI2’s showed remarkable potency in regard to antiplatelet and vasodilator actions. in order to evaluate these potencies the inhibition of arachidonic acid induced platelet aggregation in human platelet rich plasma, relaxation of bovine coronary artery (BCA) and systemic blood pressure (BP) in the anesthetized rat were determined. Platelet aggregation was inhibited by PGI2 with an IC50 approx. 3-10-9M, BP was decreased in a dose dependent manner with an ED25, of 0.23 ug/kg i.v. and a marked relaxation of BCA was observed. Similar results were obtained with PGI2-methylester. Substitution of the n-pentyl moiety by cyclohexyl, 3-furyl-2-ethyl or 3-thienyl-oxymethyl resulted in PGI2- and PGI2-methyl-ester-analogs with high biological activity, whereas substitution by T6,16-dimethyl-18-oxa-alkyl or phenoxymethyl caused a loss of activity in the models used. The potency of the prostacyclins in the platelet model seem to depend upon their ability to elevate the platelet cyclo-AMP level. Thus the antiplatelet potency of modified PGI2’s may reflect their ability to affect the adenylate cyclase system.


1979 ◽  
Vol 3 (1) ◽  
pp. 7-22 ◽  
Author(s):  
B.A. Schölkens ◽  
W. Bartmann ◽  
G. Beck ◽  
U. Lerch ◽  
E. Konz ◽  
...  

2009 ◽  
Vol 102 (09) ◽  
pp. 479-486 ◽  
Author(s):  
Zuzana Reicheltová ◽  
Martin Malý ◽  
Jiří Suttnar ◽  
Alžbòta Sobotková ◽  
Peter Salaj ◽  
...  

SummaryCongenital dysfibrinogenemia is a rare disease characterised by inherited abnormality in the fibrinogen molecule, resulting in functional defects. Two patients, a 26-year-old woman and a 61-year-old man, both with history of thrombotic events, had abnormal coagulation test results. DNA sequencing showed the heterozygous γY363N mutation (Fibrinogen Praha III) and the heterozygous Aα N106D mutation (Fibrinogen Plzeň), respectively. Fibrin polymerisation, after addition of either thrombin or reptilase, showed remarkably delayed polymerisation in both cases. Fibrinolysis experiments showed slower tPA initiated lysis of clots. SDS-PAGE did not show any difference between normal and Praha III and Plzeň fibrinogens. Both mutations had a significant effect on platelet aggregation. In the presence of either ADP or TRAP, both mutations caused the decrease of platelet aggregation. SEM revealed abnormal clot morphology, with a large number of free ends and narrower fibres of both fibrin Praha III and Plzeň. Praha III mutation was situated in the polymerisation pocket “a”. The replacement of the bulky aromatic side chain of tyrosine by the polar uncharged small side chain of asparagine may lead to a conformational change, possibly altering the conformation of the polymerisation pocket. The Plzeň mutation is situated in the coiled-coil connector and this replacement of polar uncharged asparagine residue by polar acidic aspartate changes the alpha-helical conformation of the coiled-coil connector;and may destabilise hydrogen bonds in its neighborhood. Although both mutations are situated in different regions of the molecule, both mutations have a very similar effect on fibrinogen functions and both are connected with thromboses.


Placenta ◽  
1993 ◽  
Vol 14 (1) ◽  
pp. 75-83 ◽  
Author(s):  
H. Iioka ◽  
S. Akada ◽  
T. Shimamoto ◽  
Y. Yamada ◽  
Y. Sakamoto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document